🧬 BioMed Pulse · 2026-10-25 02:01 UTC
BIOMED PULSE
Sunday, October 25, 2026 | Daily Briefing on Longevity, Viruses, and New Cures
⚡ TL;DR
The Bundibugyo virus (Ebola) outbreak in the DRC has now spread to Kenya and Nigeria, making it the largest Ebola outbreak ever recorded and a fast-moving multi-country emergency. Mood: urgent on the outbreak front; steady but cautious on longevity science.
🦠 OUTBREAKS & VIRUSES
BUNDIBUGYO VIRUS DISEASE (EBOLA) - DRC, KENYA, NIGERIA
- As of October 23, 2026, the BVD outbreak in the DRC has expanded geographically with Kenya and Nigeria now reporting imported cases, per the latest WHO Disease Outbreak News. [1]
- WHO DON-622 notes sustained, high-level transmission remains the driver; the outbreak began in Mongbwalu, Ituri Province in May 2026 and has since spread across six DRC provinces. [1] [2]
- As of the prior DON (September 25), two additional health zones were affected including Bulu in Sud-Ubangi Province on the northwest border of DRC, signaling westward geographic drift. [3]
- The outbreak is described by WHO as the largest Ebola outbreak ever reported in the DRC and expanding faster than any previous Ebola outbreak on record. [4]
- A laboratory-confirmed imported BVD case in Kenya was reported to WHO on October 5; the patient had traveled from DRC through Uganda before hospitalization. [5]
- Nigeria's imported case(s) reported alongside Kenya in DON-622 mark the third African country outside DRC affected in this outbreak. [1]
- Uganda was the first country to report cross-border transmission, with 906 suspected cases and 223 deaths among suspected cases noted as far back as May 27, 2026. [6]
- As of July 15, 2026 figures, a cumulative 2,124 confirmed cases and 828 deaths had been reported from DRC alone; numbers are substantially higher by late October. [7]
- CDC mobilized an international Ebola response in May 2026 and activated enhanced airport screening at Washington Dulles and Atlanta for travelers from affected regions. [8] [9] [10]
PNEUMONIA OF UNDETERMINED ETIOLOGY - RUSSIA
- On October 2, 2026, WHO was informed via media reports of the death of an employee of the Irkutsk Antiplague Research Institute (APRI) of Siberia and the Far East, Russian Federation, following severe pneumonia.
- The etiology remains undetermined per WHO DON-620 published October 10; WHO is monitoring this event involving a worker at a biosafety-sensitive facility.
MERS-CoV - SAUDI ARABIA
- Between January 1 and October 5, 2026, Saudi Arabia reported eight laboratory-confirmed MERS-CoV cases including one death, detected across six locations: Al Jouf, Arar, Hafr Al-Batin, Riyadh, Tabuk, and one additional site.
- MERS-CoV continues its endemic pattern of sporadic camel-to-human transmission in the Arabian Peninsula with no sustained human-to-human spread reported.
NIPAH VIRUS - INDIA
- On June 11, 2026, the Kerala State Health Department confirmed one laboratory-confirmed case of Nipah virus (NiV) in Kozhikode district; the adult male developed neurological symptoms and was hospitalized June 10, 2026.
- Kozhikode, Kerala has been the epicenter of prior NiV outbreaks in India; fruit bats of the Pteropus genus are the established reservoir.
ANDES HANTAVIRUS - CRUISE SHIP M/V HONDIUS
- WHO DON-611 (July 2, 2026) represents the fifth posting on the Andes hantavirus (ANDV) outbreak linked to the M/V Hondius cruise ship, first notified to WHO on May 2, 2026.
- CDC provided repeated response updates through June 24, 2026, noting the U.S. public risk remained extremely low but monitoring of U.S. travelers was active throughout.
YELLOW FEVER - GLOBAL
- From January 1 to May 26, 2026, six countries reported 79 human yellow fever infections; transmission activity carried over from an elevated 2025 season in the Americas, per WHO DON-610.
ANIMAL RABIES - USA
- CDC issued a statement on September 10, 2026 noting increases in animal rabies activity and associated human exposure events across the United States.
🧬 LONGEVITY & AGING
SENESCENCE AND SPINAL AGING
- A Europe PMC study (Bioact Mater) identified that NOX4-driven ferroptosis accelerates cellular senescence in intervertebral disc cells, a mechanism the authors call ferro-aging; they tested an iron-chelating, senescent-cell-targeted nanotherapy to reverse disc degeneration.
- A separate Bioact Mater paper demonstrated that RNA interference targeting mTORC1, delivered via cationized gelatin nanospheres, protected against intervertebral disc degeneration in preclinical models, with controlled release critical to efficacy.
- A third spinal study (Genes and Disease) showed the transcription factor Glis1 promotes H3K18 lactylation, a histone modification that reprograms neuronal metabolism and alleviates neuronal senescence following spinal cord injury.
- Ultrasound-responsive nanotherapy was shown to promote axonal regeneration after spinal cord injury by reactivating the CREB/miR-129-5p signaling pathway, published in Bioact Mater (September 2026).
BONE AND CARTILAGE AGING
- A single-cell transcriptomic-guided hydrogel study (Biomaterials, August 2026) designed a cascade-responsive scaffold with a bioinspired nanocellular pacemaker specifically to address the aged bone regeneration microenvironment.
- Quercetin-derived carbon dots were incorporated into ZIF-8 metal-organic frameworks and M2 macrophage-derived migrasomes to create a nanocomposite hydrogel for osteoporotic bone defect repair, published in Bioact Mater.
- A DNA-adsorbing nanozyme hydrogel reprogrammed the immune-oxidative microenvironment of osteoarthritic joints to support stem cell-based cartilage repair, published in Bioact Mater (October 2026).
- Extracellular vesicles were reviewed in Bioact Mater as context-dependent agents in osteoarthritis, acting as both pathogenic drivers and reparative signals depending on cellular microenvironment.
TISSUE REGENERATION AND ANTI-FIBROSIS
- An antifibrotic hydrogel review in Bioact Mater (September 2026) outlined mechanisms by which engineered matrices suppress TGF-beta-driven scarring to promote scarless tissue healing.
- Engineered probiotics coupling photothermal cuproptosis with biomechanical disruption and immune activation were reported as a multipronged cancer-killing strategy in Bioact Mater.
- A Lancet Digital Health study developed and validated AI foundation models (FAHR-Face) that estimate biological age and health status from facial photographs, using mechanisms tied to Vladislav Gladyshev's aging biology framework.
💊 NEW CURES & APPROVALS
HIBSAGO (BEPIROVIRSEN) - GLAXOSMITHKLINE
- FDA granted original approval (ORIG AP) to HibSago, GlaxoSmithKline's bepirovirsen, an antisense oligonucleotide targeting hepatitis B virus RNA to suppress viral replication, under NDA 221276.
- Bepirovirsen works by degrading HBV RNA across all transcript types, aiming for functional cure of chronic hepatitis B, a disease affecting an estimated 300 million people globally.
JEMPERLI (DOSTARLIMAB-GXLY) - GLAXOSMITHKLINE
- FDA processed a supplemental approval (SUPPL AP) for Jemperli (dostarlimab-gxly), GlaxoSmithKline's PD-1 checkpoint inhibitor, under BLA 761174; dostarlimab targets the PD-1/PD-L1 axis to restore anti-tumor T cell activity.
REBLOZYL (LUSPATERCEPT-AAMT) - CELGENE CORP
- FDA processed a supplemental approval for Reblozyl (luspatercept-aamt), Celgene Corporation's erythroid maturation agent that acts on the TGF-beta signaling pathway to promote late-stage red blood cell differentiation in anemia.
TOFACITINIB CITRATE - AJANTA PHARMA
- FDA granted original approval to Ajanta Pharma Ltd's generic tofacitinib citrate (ANDA 219542), a JAK1/JAK3 inhibitor used in rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.
ESTRADIOL AND LEVONORGESTREL - ZYDUS PHARMS
- FDA granted original approval to Zydus Pharmaceuticals for a combined estradiol and levonorgestrel formulation (ANDA 220407), a hormone therapy combination.
APIXABAN - TEVA PHARMACEUTICALS USA
- FDA processed an original tentative approval (ORIG TA) for Teva Pharmaceuticals USA Inc's generic apixaban (ANDA 210142), a Factor Xa inhibitor for stroke prevention and VTE treatment.
VALGANCICLOVIR HYDROCHLORIDE - ACTAVIS LABS
- FDA processed a supplemental approval for Actavis Laboratories FL Inc's valganciclovir hydrochloride (ANDA 205220), a prodrug of ganciclovir used against cytomegalovirus infections.
🧪 CLINICAL TRIALS
ALZHEIMER'S DISEASE - FUZHOU AGING BRAIN HEALTH INITIATIVE
- A new observational cohort study (NCT07891429) launched in Fujian Province, China aims to characterize Alzheimer's disease pathophysiology and evolutionary patterns in older adults, with long-term follow-up planned.
COGNITIVE IMPAIRMENT - CEREBRAL SMALL VESSEL DISEASE
- Trial NCT07891650 is enrolling 160 adults to evaluate personalized intermittent theta burst stimulation (iTBS), a noninvasive transcranial magnetic stimulation protocol, for cognitive impairment linked to cerebral small vessel disease.
COGNITIVE AGING - METABOLIC SYNDROME AND VIRTUAL REALITY
- Trial NCT07040748 is testing a multimodal immersive virtual reality intervention (Virtual-METS) combining cognitive training and physical exercise to improve cognition in middle-aged adults with metabolic syndrome and subjective cognitive complaints.
AGING AND FITNESS LONGITUDINAL STUDY - CHINA
- The China Healthy Aging and Fitness Longitudinal Study (CHALF, NCT07881094) plans to recruit approximately 8,900 older adults nationwide to investigate how physical activity, exercise, and fitness associate with aging outcomes.
BASE-EDITED GENE THERAPY - WHIM SYNDROME
- Trial NCT07775313 is testing base-edited hematopoietic stem and progenitor cell gene therapy to correct CXCR4 gene mutations causing WHIM syndrome, a rare immune disorder characterized by severe infections.
NEOANTIGEN T CELL THERAPY - HEMATOLOGIC MALIGNANCIES
- Trial NCT06904066 is testing autologous T cells transduced with retroviral vectors expressing participant-specific neoantigen-targeting T cell receptors (TCRs) against TP53 and RAS-mutant leukemias.
MOSAIC INFLUENZA VACCINE - FLUMAS-V2 WITH ALFQ ADJUVANT
- Trial NCT06863142 is evaluating FluMos-v2, a hexavalent mosaic influenza vaccine, with and without the ALFQ adjuvant, in healthy adults for safety, tolerability, and immunogenicity.
INTRANASAL COVID-19 BOOSTER - OCU500 CHADENOVIRUS VACCINE
- Phase 1 trial NCT07536308 is dose-escalating OCU500, a ChAd36 vector encoding SARS-CoV-2 spike, delivered intranasally and by inhalation in previously vaccinated adults aged 18-64.
HEPATIC ARTERY INFUSION - CARFILZOMIB FOR LIVER METASTASES
- Trial NCT07715903 (registered October 23, 2026) is evaluating hepatic artery infusion of carfilzomib, a proteasome inhibitor, in patients with liver metastatic disease previously treated with HAI pump therapy.
📢 PUBLIC HEALTH
LISTERIA OUTBREAK - ONGOING, PREPARED MEALS
- CDC as of October 30, 2026 continues urging consumers to check refrigerators and freezers for recalled prepared meal products as illnesses persist despite earlier recalls; do not eat recalled foods.
RABIES ACTIVITY - ELEVATED, USA
- CDC flagged a September 2026 increase in animal rabies cases and human exposure events nationally, urging prompt post-exposure prophylaxis evaluation for anyone bitten by a wild or unfamiliar animal.
DRUG-RESISTANT BACTERIA - SHARP RISE REPORTED
- A September 23, 2025 CDC report found a dramatic increase in dangerous drug-resistant bacteria in U.S. healthcare and community settings, underscoring the ongoing antimicrobial resistance threat.
CONGENITAL SYPHILIS - 12TH CONSECUTIVE YEAR OF INCREASE
- CDC data released September 24, 2025 show U.S. congenital syphilis cases rose for the 12th consecutive year in 2024, signaling persistent failures in antenatal screening and treatment access.
OVERDOSE DEATHS - DECLINING
- CDC provisional 2024 data showed a 27% decrease in U.S. drug overdose deaths, the largest single-year decline on record per the National Vital Statistics System.
KINDERGARTEN VACCINATION RATES - SLIGHT DECLINE
- CDC data released August 17, 2026 show kindergarten vaccination coverage remains high but fell 0.1% compared with the prior year, a small but monitored signal.
CANCER MORTALITY - LUNG CANCER DRIVING DECLINES
- The Annual Report to the Nation (September 22, 2026) highlights falling overall U.S. cancer death rates, with lung cancer mortality improvements as the primary driver.
This briefing is for informational purposes only and does not constitute medical advice. Consult qualified health professionals for clinical guidance.
📎 Sources
- Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
- Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
- Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
- Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
- Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
- Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
- Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
- CDC Mobilizes International Response Following Ebola Disease O… — CDC Newsroom
- Enhanced Ebola Airport Screening Begins at Washington-Dulles I… — CDC Newsroom
- Enhanced Ebola Airport Screening Expands to Atlanta — CDC Newsroom
Curated from official sources — WHO/CDC/ECDC/openFDA/ClinicalTrials.gov/Europe PMC. Informational only — not medical advice.
Serial 20261025-02-v116 · 2026-10-25 02:01 UTC · pulse.uzylab.com